Kerstin M. Genetay
Corporate Officer/Principal presso Newron Sweden AB
Provenienza dei contatti di primo grado di Kerstin M. Genetay
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Newron Sweden AB is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous systems. The company was founded by Jonas Cristopher Frisen and Ann Marie Janson in 1998 and is headquartered in Stockholm, Sweden.
11
| Subsidiary | Pharmaceuticals: Major | 11 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Kerstin M. Genetay tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| NEWRON PHARMACEUTICALS S.P.A. | Pharmaceuticals: Major | General Counsel Chief Executive Officer Director of Finance/CFO | |
| Newron Pharmaceuticals US, Inc. | President Director/Board Member Director/Board Member | ||
| Karolinska Institutet | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
| University of Lund | College/University | Doctorate Degree Graduate Degree Doctorate Degree | |
| CALLIDITAS THERAPEUTICS AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Hunter-Fleming Ltd.
 Hunter-Fleming Ltd. Pharmaceuticals: MajorHealth Technology Hunter-Fleming Ltd. dvelops pharmaceutical products. The company was founded by James R. Murray, John S. Fox and Ernst Wülfert in February 1999 and is headquartered in Brixham, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| INFANT BACTERIAL THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member | |
Karolinska Institutet Innovations AB
 Karolinska Institutet Innovations AB Financial ConglomeratesFinance Karolinska Institutet Innovations AB enables education, professional networking, funding, expertise in entrepreneurship and business development, and incubation opportunities for life science projects and companies. The company was founded in 1996 and is headquartered in Solna, Sweden. | Financial Conglomerates | Chief Executive Officer | |
| Astra Arcus AB | Corporate Officer/Principal | ||
| ONCOZENGE AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Drupps AB | Director/Board Member | ||
| KANCERA AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| DIAMYD MEDICAL AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| University of Hagen | College/University | Graduate Degree | |
| BIOFRONTERA AG | Pharmaceuticals: Major | Director of Finance/CFO | |
| Åbo Akademi University | College/University | Graduate Degree | |
| Newron Suisse SA | Chief Executive Officer | ||
| Ro¨kfritt AB | Director/Board Member | ||
| Nikolaus & Claudius Lohmann | Director of Finance/CFO | ||
| University of Bocconi | College/University | Undergraduate Degree | |
Coopers & Lybrand SpA
 Coopers & Lybrand SpA Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Coopers & Lybrand SpA is an Italian company. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor | |
PricewaterhouseCoopers SpA
 PricewaterhouseCoopers SpA Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., PricewaterhouseCoopers SpA is a company based in Milan, Italy. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Affibody AB
 Affibody AB Miscellaneous Commercial ServicesCommercial Services Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| LIDDS AB | Pharmaceuticals: Major | Chief Executive Officer | |
| Stockholm School of Economics | College/University | Masters Business Admin | |
| VIVESTO AB | Pharmaceuticals: Generic | Corporate Officer/Principal | |
QleanAir Scandinavia AB
 QleanAir Scandinavia AB Industrial MachineryProducer Manufacturing QleanAir Scandinavia AB provides clean air solutions that meet governmental standards. Its smoking cabinet eliminated all the negative associations relating to cigarette smoking. Their product captured the smoke before it could spread into the environment, and cleaned it with filter technique. Its solutions include smoke free smoking cabins for smoke free and odorless environments, and smoking rooms for handling various smokers. The company was founded by Peter Bjersten on October 26, 1987 and is headquartered in Solna, Sweden. | Industrial Machinery | Director of Finance/CFO | |
| QLEANAIR AB | Engineering & Construction | Director of Finance/CFO | |
| University of Stockholm | College/University | Doctorate Degree | |
| Schwarz Pharma SpA | Corporate Officer/Principal | ||
Polifarma SpA
 Polifarma SpA Drugstore ChainsRetail Trade Polifarma SpA engages in the manufacture of ethical medicines. It specializes in the provision of pharmaceutical preparations for cardiovascular, gastroenterology, central nervous system, infectious diseases, and pain and inflammation areas. The company was founded in 1919 and is headquartered in Rome, Italy. | Drugstore Chains | Sales & Marketing | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | President | |
| PERSTORP HOLDING AB (PUBL.) | Chemicals: Specialty | Corporate Officer/Principal | |
AnaMar AB
 AnaMar AB Pharmaceuticals: MajorHealth Technology AnaMar AB develops drugs and provides research services for chronic joint diseases. It focuses on the discovery, development and commercialization of novel therapeutic strategies to treat debilitating inflammation and pain. The company was founded in 1998 and is headquartered in Lund, Sweden. | Pharmaceuticals: Major | Chief Executive Officer | |
Spatial Transcriptomics AB
 Spatial Transcriptomics AB Miscellaneous Commercial ServicesCommercial Services Spatial Transcriptomics AB develops technology for RNA sequencing. Its system bridges microscopy and RNA sequencing to generate complete transcriptome data from a single intact tissue sample, and utilizes standard instrumentation for sequencing. The firm's products include ST Tissue Optimization Slide and ST Library Preparation Slide. The company was founded by Jonas Christopher Frisén, Joakim Lundeberg, and Patrik Ståhl and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer | |
| ANNEXIN PHARMACEUTICALS AB | Pharmaceuticals: Major | Chief Executive Officer | |
| KARO PHARMA AB (PUBL) | Pharmaceuticals: Major | Corporate Officer/Principal | |
Nordea Securities AB
 Nordea Securities AB Investment Banks/BrokersFinance Part of Nordea Bank Abp, Nordea Securities AB is a Swedish company that provides securities brokerage services. The company is based in Stockholm, Sweden. | Investment Banks/Brokers | Corporate Officer/Principal | |
| Pharmalink Oncology AS | Director/Board Member | ||
Busulipo AB
 Busulipo AB Pharmaceuticals: MajorHealth Technology Busulipo AB is a Swedish company that manufactures and wholesales pharmaceutical and medical technology products. The private company is based in Stockholm, Sweden. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Nefecon AB
 Nefecon AB Pharmaceuticals: MajorHealth Technology Part of Calliditas Therapeutics AB, Nefecon AB is a pharmaceutical company based in Stockholm, Sweden. The Swedish company has developed a patented oral, delayed release formulation of budesonide called nefecon, which is designed to target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models. Nefecon is derived from the targit technology, which allows for the substance to pass through the stomach and intestine without being absorbed, and to be released in a pulse-like fashion only when it reaches the lower small intestine. The company has completed a large phase 2b trial, which showed that the combination of dose and optimized release profile is required to be effective in patients with IgA nephropathy. | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
| Svezia | 31 |
| Italia | 8 |
| Germania | 5 |
| Stati Uniti | 4 |
| Regno Unito | 3 |
Settori
| Health Technology | 21 |
| Consumer Services | 9 |
| Commercial Services | 6 |
| Finance | 3 |
| Process Industries | 3 |
Posizioni
| Corporate Officer/Principal | 32 |
| Director/Board Member | 15 |
| Chief Executive Officer | 9 |
| Director of Finance/CFO | 7 |
| Doctorate Degree | 7 |
Contatti più connessi
- Borsa valori
- Insiders
- Kerstin M. Genetay
- Connessioni Società
